New Haven’s Marinus Pharmaceuticals said its stock will begin trading Thursday on the Nasdaq Global Market under the symbol MRNS.
The company, which is developing neuropsychiatric therapeutics, has priced more than 5.6 million shares at $8 each, before underwriting discounts.
Stifel and JMP Securities are book-running managers for the offering. Meanwhile, Oppenheimer & Co. is lead manager for the offering and Janney Montgomery Scott is co-manager.
Marinus said the underwriters have a 30-day option to purchase nearly 844,000 more shares to cover any over-allotments. The IPO is expected to close Aug. 5.
